Podcasts about MSC

Welcome to Season 14 Episode 38 of the ParentingAces Podcast! In this week's episode, Lisa is joined by Sam Parfitt, former top junior and collegiate player and the founder/CEO of The True Athlete Project (TAP).TAP has pioneered a holistic mindfulness-based approach that unleashes sport's potential to change lives across diverse contexts. They believe sport can play a powerful role in building a happier, healthier, more compassionate world. But too often, sport fails to live up to its potential, driven by a win-at-all-costs culture that dehumanizes people and leads to dropout, burnout, bullying, and disastrous mental health outcomes. TAP wants sport to be joyful and freeing, and to bring people together. They have become leaders in how to change the culture of sport, working with national and international governing bodies, community sports centers, schools, colleges, coaches, athletes, referees, and parents.Sam Parfitt holds an MSc in Sport Policy, Management and International Development from the University of Edinburgh, where he then became an associate tutor. His dissertation focused on the role of sport coaches as social change-makers. He is a certified mindfulness teacher and a USPTA professional tennis coach with experience coaching all ages and standards - from total beginners to internationally-ranked juniors.​While Sam suffered with poor health during his time in the US, Sam endeavored to use his experiences in sport - both positive and negative - to help others. His academic work centered around sport and identity, and he became intimately involved in establishing projects which used sport as an agent for social change. He worked extensively within the context of sport for at-risk Hispanic youths and won multiple awards for his efforts, including the 2012 UTC and City of Chattanooga public service award and the Coleman Lew & Associates Leadership Award.After working within an NCAA Division I athletics department, he was appointed director of athletics at Saint Peter's School - an independent K through 5th school in Chattanooga, Tennessee. There, he had the chance to create his own athletics program around a set of ideals that would help the children enjoy a positive start to their sporting careers. The program included a novel parkour program, sports poetry, mindfulness, and brought the school into the news for his inclusive and innovative approach to the holistic training of young athletes.During his time at St.Peter's School, Sam was also an NCAA Division I women's tennis coach, helping to take the Mocs to their best record for over twenty years.Sam has also worked with the Mastercard Scholars Foundation and advises several NGOs. He has delivered mindfulness to Olympians and Paralympians across over thirty sports.If you're interested in learning more about The True Athlete Project, visit their website at https://www.thetrueathleteproject.org. You can reach Sam directly via email at sam@thetrueathleteproject.org.As always, I am available for one-to-one consults to work with you as you find your way through the college recruiting process. You can purchase and book online through our website at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://parentingaces.com/shop/category/consult-with-lisa-stone/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.If you're so inclined, please share this – and all our episodes! – with your fellow tennis players, parents, and coaches. You can subscribe to the podcast on Apple Podcasts or via your favorite podcast app. Please be sure to check out our logo'd merch as well as our a la carte personal consultations in our ⁠⁠⁠⁠⁠⁠⁠⁠⁠online shop⁠⁠⁠⁠⁠⁠⁠⁠⁠.CREDITSIntro & Outro Music: Morgan Stone aka STØNEAudio & Video Editing: Lisa Stone

This week on the Inspiring Leadership Podcast: Meet Wing Commander Jacqui Wilkinson, a decorated senior leader in the British Royal Air Force, with over 20 years of service—and a powerful story of resilience, leadership, and transformation.

In this solo episode of Quietly Visible, Carol reflects on her personal journey from self-doubt to self-confidence, sharing how she learned to embrace her introversion and turn it into a strength. She opens up about overcoming imposter syndrome throughout her career—whether navigating organisational change, stepping into leadership roles, or writing her book—and how aligning her 'why' with her values helped her succeed.Drawing on her own experiences as well as her MSc research into belonging and psychological safety, Carol explores:✔️Why introversion is not a lack of confidence but a different way of leading and connecting✔️How to recognise and address specific areas of self-doubt rather than writing yourself off as 'not confident'✔️Practical strategies to manage imposter syndrome and reframe self-perceptions✔️The role of environment, values, and personal motivations in building lasting confidenceThis episode is both personal and practical, offering encouragement and tools for anyone who has ever felt held back by self-doubt, imposter syndrome, or the belief that they need to be someone else to succeed.Complete the free Confidence, Influence, and Impact Assessment at https://aboundingsolutions.com/taketheimpactassessment/

Thomas Agoritsas, MD, PhD, Geneva University Hospitals, Switzerland discusses Users' Guides to the Medical Literature about patient management recommendations with author Gordon H. Guyatt, MD, MSc, McMaster University. Related Content: How to Interpret and Use a Clinical Practice Guideline or Recommendation Platelet Transfusion Caring for Patients With Acute Respiratory Distress Syndrome

Stepping onto Egyptian soil in 2006, Fotoula Adrimi's soul knew that this was home on Earth. Goddess Isis lifted the veil of time from her eyes, revealing an ancient world where spiritual awakening is possible and whose mysticism can be retrieved to help life now. These pages will remind you of ancient teachings aimed at rediscovering our origin as beings of light who have come to Earth to experience and awaken. Egypt is a source of fascination that keeps calling the soul back from one lifetime to the next. What is the source of power emanating from the temples, the statues of the gods and goddesses, and the strange images on the walls? What happens when we consciously enter the vortex of etheric energy placed deliberately by the ancients? We might find that we are never the same. This book takes us on a journey through time and space, through dimensions and different realities, through self-acceptance and self-love, to lead us back into our infinite spirit, where the source of magic exists.Fotoula Adrimi, BA(Hons), MSc, is the director of the ISIS School of Holistic Health, an international school of healing arts, spiritual development, and inner transformation through vibrational energy work, enlightened teachings, shamanism, and meditation. She is part of the global network of Shamanic Teachers under Sandra Ingerman. Fotoula lives and works in Glasgow, Scotland, has taught in Germany and the Netherlands, and has led spiritual pilgrimages to Egypt. Her first book, The Golden Book of Wisdom: Ancient Spirituality and Shamanism for Modern Times, is an Amazon UK bestseller.https://www.theisisschoolofholistichealth.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

Recovery is often described as freedom, joy, and relief. But for people who have lived with eating disorders for many years or even decades, the reality is much more complicated. In this episode of Dr. Marianne-Land: An Eating Disorder Recovery Podcast, Dr. Marianne explores why recovery can feel unsafe and why ambivalence is such a common part of the process. You will hear about how eating disorders become entangled with identity, daily routines, and survival, and why letting go can feel destabilizing even when it is necessary for healing. Dr. Marianne explains how trauma, systemic oppression, sensory sensitivities, and executive functioning struggles can all make recovery feel threatening to the nervous system. She also shares how grief and ambivalence show up in long-term recovery and why both deserve compassion instead of shame. This episode highlights the importance of trauma-informed, neurodivergent-affirming, and fat-affirming care, and it offers practical ways to build a sense of safety through sensory supports, executive functioning tools, and pacing change. What You Will Learn in This Episode: Why recovery often feels unsafe instead of freeing How ambivalence is a normal and intelligent survival response The role of trauma in making recovery feel threatening How intersectionality and systemic oppression shape recovery experiences Why grief is an important but overlooked part of long-term recovery Sensory and executive functioning strategies that can support safer eating experiences Related Episodes Stages of Change & Ambivalence Around Change in Eating Disorder Recovery with Harriet Frew, MSc, @theeatingdisordertherapist_ on Apple & Spotify. Orthorexia, Quasi-Recovery, & Lifelong Eating Disorder Struggles with Dr. Lara Zibarras @drlarazib on Apple & Spotify. Navigating a Long-Term Eating Disorder on Apple & Spotify. Work With Dr. Marianne If this episode resonates with you and you are ready for support, Dr. Marianne Miller offers eating disorder therapy in California, Texas, and Washington, D.C. Her approach is trauma-informed, sensory-attuned, and affirming of neurodivergent and marginalized identities. Learn more and connect with her at drmariannemiller.com.

In the September episode of Chattering With International Cat Care, we bring together two conversations on how innovation and teamwork shape feline medicine.First, Yaiza Gómez Mejías speaks with Morgane Debuigne, winner of the JFMS Resident Best Paper Award 2024, about her article on feline supraglottic airway devices. What does the latest research reveal about their role in anaesthesia and where do they fit alongside established practice?Then, Dr Kelly St. Denis continues her discussion with Mary Ellen Goldberg on feline rehabilitation. In this second part, they explore therapies, exercises, and the practical ways veterinary teams and owners can play a role in supporting recovery. Catch up on the first part of their conversation by tuning into our July episode!For further reading material please visit:Placement of the feline V-gel Advanced supraglottic airway device and tracheal selectivity during controlled mechanical ventilation: a clinical and tomodensitometric evaluationComputed tomography assessment of V-Gel Advanced supraglottic airway device placement in catsPhysical rehabilitation of cats: 1. Common conditions benefiting from physiotherapyPhysical rehabilitation of cats: 2. Treatment therapies and exercisesFor iCatCare Veterinary Members, full recordings of each episode of the podcast are available for you to listen to at portal.icatcare.org. To become an iCatCare Veterinary Member, or find out more about our Cat Friendly schemes, visit icatcare.orgHost:Yaiza Gómez-Mejías, LdaVet MANZCVS (Medicine of Cats), RCVS CertAP (Feline Medicine), iCatCare Veterinary Community Co-ordinatorSpeakers:Morgane Debuigne, Dipl. ECVAA, Winner of the JFMS Resident Best Paper Award 2024Kelly St. Denis, MSc, DVM, DABVP (Feline), Co-editor of the Journal of Feline Medicine and Surgery and JFMS Open Reports, St Denis Veterinary Professional Corporation, Powassan, Ontario, CanadaMary Ellen Goldberg, BS, LVT, CVT, SRA, CCRVN, CVPP, VTS, VTS-LAM, VTS Hon, Certified Veterinary Pain Practitioner & JFMS Author

Dr. David Fajgenbaum, MD, MBA, MSc, is a pioneering physician-scientist, tenured professor at the Perelman School of Medicine at the University of Pennsylvania, and national bestselling author who transformed his personal battle with the rare, deadly Castleman disease into a global mission to accelerate cures for humanity's 12,000 known diseases. Diagnosed after losing his mother to cancer, Fajgenbaum endured five near-death experiences before using his medical training to identify sirolimus—a repurposed drug—as a life-saving treatment, achieving remission marking over a decade cancer-free as of 2025. A Georgetown University graduate with advanced degrees from Oxford and Wharton, he co-founded the Castleman Disease Collaborative Network (CDCN) and Every Cure, leveraging AI and drug repurposing to unlock hidden treatments, earning spots on TIME's 2025 TIME100 Health list and major media recognition for his "cure thyself" story. Through his book Chasing My Cure and speaking engagements, Fajgenbaum inspires hope, advocates for patient-driven research, and pushes for policy changes to speed up cures for rare diseases affecting millions worldwide. Shawn Ryan Show Sponsors: https://americanfinancing.net/srs NMLS 182334, nmlsconsumeraccess.org. APR for rates in the 5s start at 6.327% for well qualified borrowers. Call 866-781-8900, for details about credit costs and terms. https://bunkr.life – USE CODE SRS Go to https://bunkr.life/SRS and use code “SRS” to get 25% off your family plan. https://shawnlikesgold.com https://ROKA.com – USE CODE SRS https://simplisafe.com/srs https://USCCA.com/srs https://ziprecruiter.com/srs https://gemini.com/srs Sign up for the Gemini Credit Card: https://Gemini.com/SRS #GeminiCreditCard #CryptoRewards #Advertisement This video is sponsored by Gemini. All opinions expressed by the content creator are their own and not influenced or endorsed by Gemini. The Bitcoin Credit Card™ is a trademark of Gemini used in connection with the Gemini Credit Card®, which is issued by WebBank. For more information regarding fees, interest, and other cost information, see Rates & Fees: gemini.com/legal/cardholder-agreement. Some exclusions apply to instant rewards; these are deposited when the transaction posts. 4% back is available on up to $300 in spend per month for a year (then 1% on all other Gas, EV charging, and transit purchases that month). Spend cycle will refresh on the 1st of each calendar month. See Rewards Program Terms for details: gemini.com/legal/credit-card-rewards-agreement. Checking if you're eligible will not impact your credit score. If you're eligible and choose to proceed, a hard credit inquiry will be conducted that can impact your credit score. Eligibility does not guarantee approval. The appreciation of cardholder rewards reflects a subset of Gemini Cardholders from 10/08/2021 to 04/06/2025 who held Bitcoin rewards for at least one year. Individual results will vary based on spending, selected crypto, and market performance. Cryptocurrency is highly volatile and may result in gains or losses. This information is for general informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Consult with your tax or financial professional before investing. Dr. David Fajgenbaum Links: Website - https://davidfajgenbaum.com X - https://x.com/DavidFajgenbaum IG - https://www.instagram.com/dfajgenbaum LI - https://www.linkedin.com/in/davidfajgenbaum Every Cure - https://everycure.org Castleman Disease Collaborative Network - https://cdcn.org TED talk - go.ted.com/davidfajgenbaum TED YT - https://youtu.be/sb34MfJjurc Chasing My Cure (Amazon) - https://www.amazon.com/Chasing-My-Cure-Doctors-Action/dp/1524799637 Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode I talk to Sharissa Sebastian Deppen about the power within introverted leaders.  Introduction Sharissa Sebastian Deppen is the CEO of Leadership Mastery Alliance; a company specializing in supporting introverted servant leaders who are women in corporate leadership. She's a leadership and executive coach with an MBA, MSc in Technology Leadership and her PCC Certification from the International Coaching Federation (ICF), as well as a Myers Briggs Certified Practitioner. She has 15+ years of corporate leadership experience in addition to coaching several Fortune 100 leaders and executives. She's also a TEDx speaker and TEDx speaker coach, an award winning international keynote speaker, a writer for Forbes and the Huffington Post, a member of Forbes Coaches Council, a Professor at Southeastern University and an advisory board member at the University of South Florida. Her many years of experience include helping leaders draw on their God-given strengths and abilities, see their value and be able to bring out the best in themselves and others all while having fun, being fulfilled and not burning out! She's able to masterfully help them navigate their blind spots while thriving in their zone of genius to take their career and leadership to a level that has a significant impact on themselves, their teams and their organization.  Her clients include leaders and executives at companies such as LinkedIn, Facebook, Google, Amazon, Twitter, Microsoft, Harpo Studios, Bank of America, CNN, The United Nations, Intuit, SalesForce, BP, Fedex, Comcast, Deloitte, Accenture, Keurig Dr. Pepper, Victoria's Secret, Warner Brothers Studios, US Bank, Coinbase, Ameriprise Financial, Nestle, Virgin, Mars, Slack, Space Force, among others.   Resources mentioned in this episode Follow Sharissa: Website: HERE LinkedIn: HERE Instagram: HERE TikTok: HERE FREE Resource-Leadership Mastery Alliance: HERE   Thank you for listening. If you enjoyed this episode, please consider subscribing and leaving a review. Leave comment on what you enjoyed from the episode and if you have any suggestions for future episodes, I'd love to hear from you. Even better, share it with a friend or colleague and turn on the notifications so that you never miss an episode. It really helps the podcast gain more listeners so that we can grow our Lead From Within community. Thanks everyone! Keep reaching for your highest branch! Let's Connect Follow me on LinkedIn Here Visit my website Here Email: mthomson@curisconsulting.ca  Self-Care Guide on Amazon: Canada: HERE USA: HERE Leave me a voice note HERE and have it included on a future podcast! Just click on the "message" tab.  It is greatly appreciated!  

How is AI impacting our jobs, careers, and sense of purpose at work? Who stands to win or lose as the pace of change accelerates? In this episode Helen Beedham chats to Rob Garlick, author, consultant, and former Head of Innovation & Technology at Citi Global Insights, to unpack how artificial intelligence is reshaping opportunities, job quality, and the very skills we need to succeed, whether you're just starting out or a seasoned leader.Together, Helen and Rob explore:⭐️ How AI is already altering job availability, job quality, who's most affected and why graduates and tech workers may be the ‘canaries in the coal mine' for wider workplace shifts;⭐️ The “conditional optimism” case: why AI's full benefits might be realised only after navigating painful disruptions;⭐️ The reality behind the hype around massive productivity gains and job substitution;⭐️ How younger workers are both disadvantaged and empowered by AI, and why older workers may bring stability and ethical oversight through turbulent times;⭐️ Practical strategies for pro-human leadership: upskilling and reskilling with purpose, leveraging AI for augmentation (not just substitution), and creating stability and agency at every career stage.About Rob Garlick:Rob is an Author, Speaker, Consultant and Coach focused on the implications of AI on work and leadership. His experience includes: 1000's of meetings with C-suite and top investors globally; a front row seat for most innovation areas in the last 30 years, publishing over 60 papers on innovation topics; and over 100 talks delivered around the world in recent years on the Future of Work. Rob was promoted to Managing Director at Citibank in 2006, and managed, mentored and coached for 20+ years.With over 30 years of experience in Investment Banking and Fund Management, Robs' roles included: Head of Innovation & Technology at Citi Global Insights; Head of Citi Research EMEA, leading the team's (of c.200) rise in the Institutional Investor surveys, from: #7 to #1 in UK, #9 to #2 in Western European, and #7 to #1 globally; Global Product Head at Citi Research; Head of Citi's US Equity Sales desk; TMT sales; Fund Manager. Rob passed the AIIMR (Associate of the Institute of Investment Management & Research) as a prize-winner in Interpretation of Accounts & Corporate Finance. Among other qualifications, Rob holds a BSc (Econ) degree in Accounting and Management, an MSc in Coaching and Behavioural Change and is a qualified Executive Coach. Links:Visit Helen's website www.helenbeedham.com.Check out Helen's award-winning business book: The Future of Time: how 're-working' time can help you boost productivity, diversity and wellbeing.Leave a book review on Amazon here.Get in touch about Helen's Time-Intelligent Teams workshops or view/download a flier here.Join her mailing list here.What does freedom at work mean to you? Take my short survey here.Pre-order my new book People Glue: hold on to your best people by setting them free  (out Jan 2026) and become a book supporter to gain exclusive book-related invitations and offers. Follow Rob Garlick on Linked In here.Loved this episode?  Follow The Business of Being Brilliant, rate and review the show, and share it with friends and colleagues who care about building brighter, fairer workplaces.

Capitulo 219 de Negocios de Otro Planeta conversando con Cesar Monroy, PsyD y MSc en Behavioral Neuroscientist, CSO de Seele Neuroscience, Profesor, autor, entre otros sobre el Neuromarketing su mirada, la Psicología Social y el IAT, sobre las emociones y su territorialidad entre otros. Si quieres conectar con Cesar su Linkedin es https://www.linkedin.com/in/cesar-andres-monroy-fonseca-psyd-msc-5b5b7621/ la web de su Consultora es https://www.seele-consulting.com/ Su libro es https://www.amazon.com/-/es/Prof-Cesar-Monroy-Fonseca-MSc/dp/1977687040 Si te gusto el podcast suscríbete, estaré haciendo mas como estos, dale me gusta y compártelo para que otros lo puedan disfrutar.

I detta avsnitt intervjuar jag Jenny Forsberg, MSc, leg. fysioterapeut, Region Örebro, som är osteoporosexpert och har varit med och startat upp osteoporosskola i regionen.Varför är osteoporos något att bry sig om?Vad är en osteoporosskola och vad innehåller den?Vilka utmaningar finns det för fysioterapeuter vid möte och behandling av patienter med osteoporos?Vad finns det för myter och missuppfattningar om osteoporos?Vad bör en fysioterapeut tänka extra på vid möte av dessa patienter?Allt detta och mer pratar vi om i avsnittet. Jag ber om ursäkt för det dåliga ljudet på min sida.

As we approach our 1 MILLION plays marker, we wanted to take you on a peek behind the scenes! Get to know us a little bit more in this special episode where we discuss the podcast, take you behind the scenes on content and production, and share a bit more about ourselves.Thank you to our sponsors:✨ Upstep: Custom orthotics, molded from the comfort of your home. Use code RUNTOTHEFINISH at https://www.upstep.com/?ref=cajmuang for $20 off your purchase.✨ Tailwind: Complete sport nutrition made simple, including hydration mixes, high-carb sport drinks, endurance fuel, and recovery mixes. Use code TREADLIGHTLY20 at https://tailwindnutrition.com/TREADLIGHTLY for 20% off your first purpose.In this episode, you will learn:✅ How we feel about the podcast at 1M listens in✅ How we curate episodes and choose interviews✅ Our backgrounds with running and sport✅ Laura's experience getting her MSc in Applied Exercise Science✅ Amanda's experience writing her book✅ What's shaped our running✅ Our takes on the current state of runningLet's stay connected:➡️ Tread Lightly Running Podcast on Instagram: https://www.instagram.com/treadlightlyrunning/➡️ Laura Norris Running on Instagram: https://www.instagram.com/lauranorrisrunning/➡️ Hundreds of evidence-based training tips on Laura's website: https://lauranorrisrunning.com/➡️ Run to the Finish on Instagram: https://www.instagram.com/runtothefinish/?hl=en➡️ Thousands of running gear reviews and training guides:https://runtothefinish.com/

Welcome to the thirty-sixth episode of the Zoology Ramblings Podcast! In this episode, Emma and Robi talk about their recent meet up at the Ealing Beaver Project for a Big Gay Beaver Day. Robi also shares some exciting news of eDNA and sniffer dogs rediscovering lost Sumatran rhinos. Emma then talks about the Ethiopian wolves for her species of the week, including an exciting new discovery of them feeding on nectar. Robi then talks about the ingeniously adapted antbed parrot moth that lives in temperature-regulated termite mounds. Emma and Robi end by delving into Scottish wildcats and their suitability for reintroduction across the UK. Robi Watkinson is a Conservation Biologist and wildlife filmmaker specialising in the spatial and movement ecology of large carnivores, camera trapping survey methods, rewilding, metapopulation dynamics and conservation planning. He has an MSc in Conservation Biology from the FitzPatrick Institute of African Ornithology, and the Institute of Communities and Wildlife in Africa, University of Cape Town. He is based between Cape Town and London, and has strong interests in equitable and inclusive conservation, palaeontology and wildlife taxonomy and evolution!Emma Hodson is a Zoologist and wildlife content creator, currently working in the community and engagement team at Avon Wildlife Trust. Emma's role as a Wildlife Champions Project Officer involves supporting and upskilling people to take action for nature in their local communities. Emma has experience in remote wildlife fieldwork, and has been part of Arctic fox, macaw and cetacean research teams in Iceland, Peru and Wales respectively. She has also been involved in animal care and rehabilitation work in Costa Rica and South Africa. Emma is particularly passionate about the interface between community engagement and wildlife monitoring, and enjoys running workshops and giving talks on topics including camera trapping, beaver ecology and rewilding. You can watch "Rewilding A Nation" for free on WaterBear by following this link: https://www.waterbear.com/watch/rewilding-a-nation . You can follow more of our weird and wonderful wildlife adventures on instagram: @zoologyramblingspodcast & @robi_watkinson_wildlife & @emma_hodson_wildlife

In Episode 3 "Pharmaceutical preventative measures" of the series "How to prevent anxiety in children undergoing urological procedures", MSc. Gülhan Karaöz-Bulut (NL) and Dr. M. İrfan Dönmez (TR) discuss how medications can support anxiety reduction in paediatric urological care. They begin by emphasising that sedation should not be a goal on its own but part of a broader, child-centred strategy aimed at preventing trauma and building trust. The episode reviews several commonly used agents - nitrous oxide, midazolam, dexmedetomidine, clonidine and ketamine - with clear explanations of their benefits, limitations, and suitability for different procedures.The speakers provide guidance on how each medication affects the child's experience, with practical considerations such as onset time, duration, side effects and how they may impact diagnostic results. Special attention is given to the impact of sedatives on urodynamic studies, highlighting where certain agents (like dexmedetomidine or ketamine) may alter bladder function. They also address administration methods, such as intranasal and oral routes, and the importance of planning around food intake and hydration.Throughout, the discussion underscores that medication should be tailored to the individual child and procedure, always supported by experienced clinical staff. The episode closes with a strong reminder that safe and effective sedation enhances both procedural success and the child's well-being.*See references and additional research information hereFor more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Discover expert insights on kidney stone prevention and management in this podcast episode featuring a physician, dietitian, pharmacist, and patient. Learn about key kidney stone risk factors and explore how dietary adjustments can reduce stone recurrence. Experts discuss fluid intake strategies, medication considerations, surgical indications, and even unconventional questions about roller coasters' impact on stone passage. Tune in for actionable advice, myth-busting discussions, and interprofessional perspectives.   On today's episode we heard from: Melanie Betz, MS, RD, CSR, FNKF, FAND is a nationally recognized renal dietitian and the Founder & CEO of The Kidney Dietitian. She is a Certified Specialist in Renal Nutrition and a Fellow of both the National Kidney Foundation and the Academy of Nutrition & Dietetics. Melanie has published extensively on kidney stone prevention and nutrition, and has presented at numerous state, national, and international conferences on the topic. Through her clinical work, research, and educational outreach, she is dedicated to helping patients and professionals understand the critical role of diet in kidney health. Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS is a Clinical Associate Professor at West Virginia University School of Pharmacy and a Clinical Pain & Addiction Pharmacist. With expertise in pain management, substance use disorders, and geriatric care, he brings both clinical and personal perspectives to kidney stone discussions. Mark has shared his experience through the Pain Pod podcast, PAINWeek presentations, and a published article detailing his own kidney stone journey. Mary Raines, CRA is a retired clinical research associate with more than 30 years of experience in medical research. After learning she needed a kidney transplant, she dedicated herself to advocacy and now serves as a Patient Advocate with the National Kidney Foundation and other kidney health organizations. Mary brings both professional expertise and personal experience to her work, amplifying the voices and needs of people living with kidney disease. Andrew Rule, MD, MSc is a Professor of Medicine and Consultant Nephrologist at the Mayo Clinic in Rochester, Minnesota. He divides his time between clinical care, research, and education, with a particular focus on kidney stone disease and its link to chronic kidney disease. Dr. Rule has published extensively on the epidemiology of kidney stones and provides specialized care in the Mayo Clinic's nephrology stone clinic. Bryan Tucker, DO, MS, FASN is an Assistant Professor of Medicine in Nephrology at Baylor College of Medicine, where he serves as a clinician educator teaching medical students, residents, and fellows while caring for patients in both inpatient and outpatient settings. He holds a master's degree in nutrition from Columbia University and completed his nephrology fellowship at Yale. A Fellow of the American Society of Nephrology, Dr. Tucker has authored numerous peer-reviewed publications and book chapters and is an active contributor to The Kidney Commute podcast.   Additional Resources: Kidney Stone Information Earn CME Credit Here Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

In this episode, host Aebhric O'Kelly kicks off the new academic year and reflects on the growth of the College of Remote and Offshore Medicine (CoROM), which will celebrate its 10-year anniversary next year. What began in 2016 with just 16 students has grown into an international institution with over 100 students across four degree programmes.This episode features conversations with the leaders of CoROM's three postgraduate programmes:Dr Ella Corrick – Director of the Doctorate in Health Sciences (DHS), who discusses the growth of the doctoral cohort, the possibility of transitioning to a PhD programme, and the vital role of building a strong online academic community.Dr Csaba Dioszeghy – Programme Manager of the MSc in Austere Critical Care (ACC), who shares upcoming updates, including flexible online pathways, new elective modules in ultrasound and paediatric critical care, and stronger international clinical placement partnerships.Dr Nick Zuber – Programme Director of the Masters in Global Health (MGH), who explains the difference between global and public health, the diverse career opportunities for graduates, and how this degree prepares clinicians for leadership roles in international healthcare systems and disaster relief.

Editor-in-Chief Cecelia E. Schmalbach, MD, MSc, is joined by senior author Colin T. Huntley, MD, and Associate Editor Boyd Gillespie, MD, to discuss how long-term changes in body mass index (BMI) following hypoglossal nerve stimulation (HGNS) impact surgical success as outlined in the paper "Impact of Postoperative Weight Changes on Hypoglossal Nerve Stimulation Success for Obstructive Sleep Apnea," which published in the September 2025 issue of Otolaryngology- Head and Neck Surgery. Click here to read the full article.

In this episode, we discuss manual therapy. We explore: Patient expectations of manual therapyHow does manual therapy work? Current evidence for manual therapyIs manual therapy an important part of our Physiotherapy toolkit? How is the current teaching of manual therapy? What is the future of manual therapy in Physiotherapy? How manual therapy differs between the public and private settingsJohnny Smith is the Director of Thorpes Physiotherapy and has worked in private practice for the last 11 years. Prior to that, he was an Extended Scope Physiotherapist in the NHS. He qualified in 2003 and completed his MSc in Musculoskeletal Medicine in 2008.  He have been teaching with SOMM since 2008 and is currently the Chair of Education for the Society and Module Coordinator for the Foundation courses. He is also an injection therapist.Darren currently works as an Advanced Clinical Physiotherapist in Cumbria. He qualified from Manchester Metropolitan University in 2009 and has worked in a variety of settings in the NHS over the past 16 years. He completed his MSc in Musculoskeletal medicine in 2017 and following this completed my Teaching Fellowship with SOMM and have been lecturing on SOMM courses since then. He is now a module co-ordinator on the foundation diploma. He is an injection therapist and a non-medical prescriber. If you like the podcast, it would mean the world if you're happy to leave us a rating or a review. It really helps!Our host is @James_Armstrong_Physio from Physio Network

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8009 Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/37272512/ Plain Language Summary of the KarMMa-3 Study of Ide-cel or Standard of Care Regimens in People With Relapsed or Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38651976/ CAR T-Cell Therapy Toxicity https://www.ncbi.nlm.nih.gov/books/NBK592426/ Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience https://pubmed.ncbi.nlm.nih.gov/28205024/ Incidence and Outcomes of Cytomegalovirus Reactivation After Chimeric Antigen Receptor T-Cell Therapy https://pubmed.ncbi.nlm.nih.gov/38838226/ Long-Acting Granulocyte Colony-Stimulating Factor in Primary Prophylaxis of Early Infection in Patients With Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35064823/ Revisiting the Role of Alkylating Agents in Multiple Myeloma: Up-to-Date Evidence and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/37244325/ Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma: Updates and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/38660139/ FDA Eliminates REMS for Approved CAR T-Cell Therapies https://www.aabb.org/news-resources/news/article/2025/06/30/fda-eliminates-rems-for-approved-car-t-cell-therapies

Today, I am delighted to reconnect with two previous guests, Dr. Darren Candow. Dr. Candow is a distinguished professor and an internationally renowned researcher on creatine monohydrate, nutrition, and physical activity, whom I had the pleasure of speaking with on Episode 301, where we discussed creatine.  We are doing an AMA session today, delving into various themes surrounding creatine, from debunking outdated RDA recommendations to exploring the synergies between strength training and creatine efficacy. We examine the cognitive benefits of creatine, investigating its interactions with caffeine and its implications for bone health, hydration, anabolic resistance, and metabolic health.  You will find today's AMA session as enlightening and enriching as I did while recording it. IN THIS EPISODE YOU WILL LEARN: The safety and efficacy of creatine as a supplement How creatine increases muscle mass and reduces protein catabolism The benefits of combining creatine with protein  Is it better to take creatine before or after a workout? How creatine supplementation may improve brain performance and mental clarity Why exercise is essential for those who want to experience the benefits of creatine for maintaining their bone health The benefits of resistance-band workouts for post-menopausal women Are there any age-related limits for creatine supplementation? Bio: Dr. Darren Candow Dr. Darren Candow, PhD, CSEP-CEP, is Professor and Director of the Aging Muscle and Bone Health Laboratory in the Faculty of Kinesiology and Health Studies at the University of Regina, Canada. The overall objectives of Dr. Candow's research program are to develop effective lifestyle interventions that incorporate nutrition (primarily creatine monohydrate) and physical activity (resistance training), with practical and clinical relevance for improving musculoskeletal aging and reducing the risk of falls and fractures. Dr. Candow has published over 120 peer-refereed journal manuscripts, supervised over 20 MSc and PhD students, and received research funding from the Canadian Institutes of Health Research, Canada Foundation for Innovation, the Saskatchewan Health Research Foundation, the National Institute of Health, and the Nutricia Research Foundation. In addition, Dr. Candow serves on the editorial review boards for the Journal of the International Society of Sports Nutrition, Nutrients, and Frontiers. Connect with Cynthia Thurlow Follow on X ⁠Instagram⁠ ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to ⁠support@cynthiathurlow.com⁠ Connect with Dr. Darren Candow On⁠ Instagram⁠ and X  Previous Episode Mentioned: ⁠Ep. 301 Creatine: The Best Supplement for Better Bones & Brain Health with Darren Candow, PhD, CSEP-CEP⁠

Natalie Lawrence is an author and illustrator who explores our relationship with the natural world, looking through multiple lenses - from the biological to the mythic and psychoanalytic. She completed a MSc and Ph.D. in History and Philosophy of Science at Cambridge, exploring the making and meanings of monstrous creatures in seventeenth century Europe. She published her first book as a teenager, Feathers and Eggshells, inspired by Hampstead Heath and the birds she was entranced by as a child, and published Planta Sapiens with Paco Calvo in 2022. She has also given a TedX talk, appeared on BBC Radio, and worked with installation artists.  In this chat, we talk about humans' fascination for monsters, how the walrus was originally conceived of as being a monster, the Hydra of Hamburg, cryptids as contemporary monsters and the ways in which our understanding of what is real and what exists has changed over the centuries. Buy Enchanted Creatures: Our Monsters and Their Meanings: https://uk.bookshop.org/a/12992/9781474619035 Find Natalie on Instagram: https://www.instagram.com/natalie.j.lawrence/ And her website: https://nataliejlawrence.com/ Get your free guide to home protection the folklore way here: https://www.icysedgwick.com/fab-folklore/ Become a member of the Fabulous Folklore Family for bonus episodes and articles at https://patreon.com/bePatron?u=2380595 Buy Icy a coffee or sign up for bonus episodes at: https://ko-fi.com/icysedgwick Fabulous Folklore Bookshop: https://uk.bookshop.org/shop/fabulous_folklore Pre-recorded illustrated talks: https://ko-fi.com/icysedgwick/shop Request an episode: https://forms.gle/gqG7xQNLfbMg1mDv7 Get extra snippets of folklore on Instagram at https://instagram.com/icysedgwick Find Icy on BlueSky: https://bsky.app/profile/icysedgwick.bsky.social 'Like' Fabulous Folklore on Facebook: https://www.facebook.com/fabulousfolklore/

Presented by Lauren S. Hughes, MD, MPH, MSc, MHCDS, University of ColoradoSTFM Conference on Practice & Quality Improvement 2025 Opening Session | Monday, September 8, 2025As value-based care (VBC) continues to reshape the health care landscape, it is critical that family medicine residency programs prepare the next generation of physicians to not only adapt to policy changes but to lead them. This session explores how physician engagement at the state and federal levels can directly influence primary care transformation—and how those lessons can be brought back to the clinic and the classroom.Drawing on firsthand experience from launching the Pennsylvania Rural Health Model, a multi-payer global budget model focused on rural and frontier hospitals, and co-chairing the National Academies of Sciences, Engineering, and Medicine (NASEM) Standing Committee on Primary Care, Dr Hughes will share insights on how to drive high-impact policy change through coalition building, data-driven decision making, and visionary leadership. These experiences will be directly tied to strategies for training future family physicians to navigate and influence the evolving world of VBC.Special attention will be given to the implications of VBC in rural and underserved communities, where innovation leverages robust community partnerships, deep knowledge of local health care needs, and a strong commitment to well-being. The talk will also explore how the current federal administration's policy directions may influence VBC and graduate medical education – and how training programs can remain agile and proactive in this shifting environment.Attendees will leave better equipped to train, support, and inspire future family physician leaders, those who can bridge the gap between policy and practice to deliver high-quality, equitable primary care.Learning ObjectivesUpon completion of this session, participants should be able to:Describe how physician leaders can influence health policy at the state and federal levels by exploring examples focused on rural health and primary care.Identify effective strategies to teach residents about the evolving value-based care landscape, especially in rural and underserved communities.Discuss the potential impact of the current federal administration's policies on value-based care initiatives and residency training.Copyright © Society of Teachers of Family Medicine, 2025Lauren S. Hughes, MD, MPH, MSc, MHCDSLauren S. Hughes, MD, MPH, MSc, MHCDS, FAAFP, is the state policy director of the Farley Health Policy Center and associate professor of family medicine, both at the University of Colorado, where she researches how to strengthen primary care infrastructure, transform rural health care delivery, and advance behavioral health integration. Dr Hughes previously served as deputy secretary for health innovation in the Pennsylvania Department of Health, where she launched the state's Prescription Drug Monitoring Program and the Pennsylvania Rural Health Model, a new payment and delivery model co-designed with the CMS Innovation Center that transitions rural hospitals from fee-for-service to multi-payer global budgets.Dr Hughes is a former chair of the American Board of Family Medicine and an alumna of the Robert Wood Johnson Foundation Clinical Scholars Program. She currently serves as chair of the Rural Health Redesign Center Organization Board of Directors and is a member of the Primary Care Payment Reform Collaborative convened by the Colorado Division of Insurance. In 2018, she was selected as a presidential leadership scholar by former US Presidents Bill Clinton and George Bush Jr., and in 2023, she was named as the co-chair of the National Academies of Sciences, Engineering, a

Send us a textLive from SLAS Europe 2025 in Hamburg, host Emily Yamasaki, PhD, speaks with Lukas Gaats, MBA, MSc, CEO of mo:re (Modern Research) who is a winner of the SLAS Europe 2025 New Product Award. Based in Hamburg, mo:re is revolutionizing 3D cell culture automation with a modular, biology-first platform designed for organoids, spheroids, and tumor models.Lukas shares his journey from academia (studying regenerative medicine and bioprinting in Australia) to founding mo:re after identifying the need for standardized, reproducible 3D cell cultures. Frustrated by the variability in manual techniques, the company developed a modular robotic system that integrates hardware, software and wetware (biology protocols). The MO:BOT is a user-friendly robotic and software platform that sets a new benchmark for medical research studies. It utilizes automation and AI to enhance cell survival and consistency, even in long-term studies, resulting in improved traceability and reproducibility for research and regulatory purposes.Learn more about mo:re by visiting:more.scienceKey Highlights:SLAS Innovation AveNEW Roots: mo:re's 2023 debut as a prototype evolved into a commercialized platform, now backed by seed funding.FDA's Animal Testing Phase-Out: Lukas discusses how this regulatory shift boosts demand for human-relevant 3D models.Hamburg's Biotech Scene: An emerging hub with talent from EMBL and Fraunhofer, though still nascent for startups.Stay connected with SLAS:www.slas.orgFacebookXLinkedInInstagramYouTubeAbout SLASSLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and globalSLAS2026 International Conference & Exhibition February 7-11, 2026 Boston, MA SLAS Europe 2026 Conference and Exhibition 19-21 May 2026 Vienna, Austria View the full events calendar

Exploring the Efficacy of BMAC and ADSC Injections in Knee Osteoarthritis   Hosts: David Rosenblum,MD Overview: In this episode, we delve into a recent study published in the Indian Journal of Orthopaedics that compares the therapeutic efficacy of Bone Marrow Aspirate Concentrate (BMAC) and Adipose-Derived Stem Cells (ADSCs) for treating knee osteoarthritis (OA). The study aims to provide insights into the effectiveness of these regenerative treatments and their correlation with mesenchymal stem cell (MSC) cellularity. Key Points Discussed: Background on Osteoarthritis: Definition and impact of OA, particularly in older populations. Overview of traditional treatments and the shift towards regenerative medicine. Study Objectives: To compare the efficacy of BMAC and ADSC injections in symptomatic knee OA patients. To analyze MSC quantity and quality in harvested tissues from both sources. Methodology: Description of the study design involving 60 patients with knee OA. Details on patient demographics, injection protocols, and follow-up assessments (VAS, WOMAC, ROM). Results: Significant improvements in clinical scores for both BMAC and ADSC groups at 6 months. Discussion on the lack of significant correlation between MSC quantity and treatment efficacy. Insights into the success rates of MSC cultures from both bone marrow and adipose tissue. Conclusions: Both treatments demonstrated clinical improvements, with no substantial differences between them. BMAC showed higher MSC counts and faster recovery rates, but further research is needed to understand the underlying factors affecting efficacy. Implications for Clinical Practice: Considerations for clinicians when choosing between BMAC and ADSC treatments. Future directions for research in regenerative therapies for knee OA. References: Vitali, M., Ometti, M., Montalbano, F., et al. (2025). Bone Marrow Aspirate Concentrate (BMAC) Versus Adipose-Derived Stem Cells (ADSCs) Intra-articular Injection Therapeutic Efficacy in Knee OA Correlated to Their Mesenchymal Stem Cell (MSC) Cellularity: An Exploratory Comparative Pilot Study. Indian Journal of Orthopaedics. https://doi.org/10.1007/s43465-025-01525-z Listener Engagement: Join the conversation! Share your thoughts on BMAC and ADSC treatments for knee OA on social media using #JournalClubPodcast. Don't forget to subscribe for more discussions on the latest research in orthopaedics and regenerative medicine.

Exploring the Efficacy of BMAC and ADSC Injections in Knee Osteoarthritis   Hosts: David Rosenblum,MD Overview: In this episode, we delve into a recent study published in the Indian Journal of Orthopaedics that compares the therapeutic efficacy of Bone Marrow Aspirate Concentrate (BMAC) and Adipose-Derived Stem Cells (ADSCs) for treating knee osteoarthritis (OA). The study aims to provide insights into the effectiveness of these regenerative treatments and their correlation with mesenchymal stem cell (MSC) cellularity. Key Points Discussed: Background on Osteoarthritis: Definition and impact of OA, particularly in older populations. Overview of traditional treatments and the shift towards regenerative medicine. Study Objectives: To compare the efficacy of BMAC and ADSC injections in symptomatic knee OA patients. To analyze MSC quantity and quality in harvested tissues from both sources. Methodology: Description of the study design involving 60 patients with knee OA. Details on patient demographics, injection protocols, and follow-up assessments (VAS, WOMAC, ROM). Results: Significant improvements in clinical scores for both BMAC and ADSC groups at 6 months. Discussion on the lack of significant correlation between MSC quantity and treatment efficacy. Insights into the success rates of MSC cultures from both bone marrow and adipose tissue. Conclusions: Both treatments demonstrated clinical improvements, with no substantial differences between them. BMAC showed higher MSC counts and faster recovery rates, but further research is needed to understand the underlying factors affecting efficacy. Implications for Clinical Practice: Considerations for clinicians when choosing between BMAC and ADSC treatments. Future directions for research in regenerative therapies for knee OA. References: Vitali, M., Ometti, M., Montalbano, F., et al. (2025). Bone Marrow Aspirate Concentrate (BMAC) Versus Adipose-Derived Stem Cells (ADSCs) Intra-articular Injection Therapeutic Efficacy in Knee OA Correlated to Their Mesenchymal Stem Cell (MSC) Cellularity: An Exploratory Comparative Pilot Study. Indian Journal of Orthopaedics. https://doi.org/10.1007/s43465-025-01525-z Listener Engagement: Join the conversation! Share your thoughts on BMAC and ADSC treatments for knee OA on social media using #JournalClubPodcast. Don't forget to subscribe for more discussions on the latest research in orthopaedics and regenerative medicine.

La ampliación del aeropuerto de Málaga hasta los 36 millones de pasajeros. La junta pretende licitar a principios de 2026 el proyecto de ampliación de la Ciudad de la Justicia de Málaga, cuya nueva imagen quiere presentar antes de que acabe este año. La compañía naviera de cruceros MSC cerrará este año con 90.000 pasajeros en el puerto de Málaga. Benagalbón acoge este sábado la trigésima edición del concurso tradicional de verdiales. En deportes, el Unicaja buscará hoy a las 14h peninsular sella el pase a la final de la copa internacional ante el conjunto japonés Utsunomiya Brex y el Málaga afrontará el derbi en la Rosaleda ante el Cádiz. En nuestra entrevista de hoy hablamos con María José Domingo, psicóloga y presidenta de AFA, para celebrar el día mundial del Alzheimer que es este domingo.Escuchar audio

Matt Zemon, MSc, is an educator, author, and leader in psychedelic wellness who focuses on the impact of psychedelics on mental health. He is the best-selling author of Psychedelics for Everyone, Beyond the Trip, and The Veteran's Guide to Psychedelics. His work centers on expanding access to psychedelic therapies, supporting veterans, and helping people find purpose, connection, and healing. In this episode… Psychedelics have moved from counterculture to boardroom, and more entrepreneurs are turning to them for healing and personal growth. But can these substances really transform the way business leaders think, feel, and lead? According to Matt Zemon, a bestselling author and educator in psychedelic wellness, the answer is yes. He explains how a guided journey helped him reconnect with his late mother, opening the door to profound emotional healing. He highlights the importance of mindset, environment, and source when approaching these medicines responsibly. For Matt, psychedelics didn't just shift his inner world; they made him a more present father, a more grounded entrepreneur, and an advocate for veterans and others seeking transformation. Tune in to this episode of the Smart Business Revolution Podcast as John Corcoran interviews Matt Zemon, an educator, author, and leader in psychedelic wellness, to discuss how psychedelics are helping entrepreneurs heal and grow. Matt also shares insights on the therapeutic potential of psilocybin, MDMA, and 5-MeO-DMT. Discover how psychedelics can enhance emotional availability, why set and setting are vital for safety, and how these tools are supporting veterans with PTSD.

Alaska Storm Forces Cruise Cancellations and Reroutes is today's lead story on Wednesday Travel and Cruise Industry Podcast, September 17, 2025 with Chillie Falls. Also this morning, Wonder of the Sea Returns After Onboard Brawl; Xcel Sea Trials; Pole Dancing Goes Wrong; Rent to Own at Sea; Texas Themed Entertainment from MSC; Carnival Crew Sentenced; Brazil to Auction Terminals; and lots more LIVE at 11 AM EDT. CLICK for video feed #wednesdaytravelandcruiseindustrypodcast #travelandcruiseindustrynews #podcast #cruisenews #travelnews #cruise #travel #chilliescruises #chilliefalls #whill_us Thanks for visiting my channel. NYTimes The Daily, the flagship NYT podcast with a massive audience. "Vacationing In The Time Of Covid" https://nyti.ms/3QuRwOS To access the Travel and Cruise Industry News Podcast; https://cms.megaphone.fm/channel/trav... or go to https://accessadventure.net/ To subscribe: http://bit.ly/chi-fal I appreciate super chats or any other donation to support my channel. For your convenience, please visit: https://paypal.me/chillie9264?locale.... Chillie's Cruise Schedule: https://www.accessadventure.net/chillies-trip-calendar/ For your mobility needs, contact me, Whill.inc/US, at (844) 699-4455 use SRN 11137 or call Scootaround at 1.888.441.7575. Use SRN 11137. YouTube: https://www.youtube.com/ChilliesCruises Facebook: https://www.facebook.com/chillie.falls X: https://x.com/ChillieFalls Learn more about your ad choices. Visit megaphone.fm/adchoices

Exploring the Efficacy of BMAC and ADSC Injections in Knee Osteoarthritis   Hosts: David Rosenblum,MD Overview: In this episode, we delve into a recent study published in the Indian Journal of Orthopaedics that compares the therapeutic efficacy of Bone Marrow Aspirate Concentrate (BMAC) and Adipose-Derived Stem Cells (ADSCs) for treating knee osteoarthritis (OA). The study aims to provide insights into the effectiveness of these regenerative treatments and their correlation with mesenchymal stem cell (MSC) cellularity. Key Points Discussed: Background on Osteoarthritis: Definition and impact of OA, particularly in older populations. Overview of traditional treatments and the shift towards regenerative medicine. Study Objectives: To compare the efficacy of BMAC and ADSC injections in symptomatic knee OA patients. To analyze MSC quantity and quality in harvested tissues from both sources. Methodology: Description of the study design involving 60 patients with knee OA. Details on patient demographics, injection protocols, and follow-up assessments (VAS, WOMAC, ROM). Results: Significant improvements in clinical scores for both BMAC and ADSC groups at 6 months. Discussion on the lack of significant correlation between MSC quantity and treatment efficacy. Insights into the success rates of MSC cultures from both bone marrow and adipose tissue. Conclusions: Both treatments demonstrated clinical improvements, with no substantial differences between them. BMAC showed higher MSC counts and faster recovery rates, but further research is needed to understand the underlying factors affecting efficacy. Implications for Clinical Practice: Considerations for clinicians when choosing between BMAC and ADSC treatments. Future directions for research in regenerative therapies for knee OA. References: Vitali, M., Ometti, M., Montalbano, F., et al. (2025). Bone Marrow Aspirate Concentrate (BMAC) Versus Adipose-Derived Stem Cells (ADSCs) Intra-articular Injection Therapeutic Efficacy in Knee OA Correlated to Their Mesenchymal Stem Cell (MSC) Cellularity: An Exploratory Comparative Pilot Study. Indian Journal of Orthopaedics. https://doi.org/10.1007/s43465-025-01525-z Listener Engagement: Join the conversation! Share your thoughts on BMAC and ADSC treatments for knee OA on social media using #JournalClubPodcast. Don't forget to subscribe for more discussions on the latest research in orthopaedics and regenerative medicine.

MSC's Dan Short on its new Alaska programme.

Tyler W. LeBaron, MSc, Ph.D., is the founder and executive director of the nonprofit Molecular Hydrogen Institute. With a background in biochemistry, physiology, and exercise science, he teaches exercise physiology and chemistry labs at Southern Utah University as an adjunct instructor. He interned at Nagoya University in Japan's Department of Neurogenetics, researching the molecular mechanisms of hydrogen gas on cell-signaling pathways. Tyler is a director of both the International Hydrogen Standards Association (IHSA) and the International Molecular Hydrogen Association (IMHA). He speaks at medical and academic conferences worldwide, collaborates with researchers globally, and works to advance the education and awareness of hydrogen as a therapeutic medical gas. Outside the lab, he trains in running and competes in arm wrestling. Alex Tarnava is a self-taught scientist, inventor, and author whose work bridges biomedical innovation, sovereign health, and philosophical disruption. He invented the world’s only open-cup molecular hydrogen tablet—a patented delivery system that has become the most studied and widely adopted form of hydrogen therapy, featured in over 21 published clinical trials. Alex has co-authored 17 peer-reviewed papers, with more in press and under review. He is also the co-inventor—alongside Tyler—of Inhale H₂, the first safe and effective hydrogen inhalation system. His leadership in the field led the Molecular Hydrogen Institute (MHI) to appoint him as the first chairman of its Research Committee. Full show notes: bengreenfieldlife.com/inhalehydrogen Episode Sponsors: LeelaQ: Not only do LeelaQ’s products neutralize EMFs, increase ATP production, optimize HRV, and improve blood flow, but they've been third-party proven to do so in placebo-controlled double-blind studies. Visit leelaq.com and use code BEN10 for 10% off. Gameday Men’s Health: Gameday Men's Health offers science-backed, physician-led men's health optimization with personalized protocols for testosterone, peptide therapy, ED treatment, and more—helping you perform at your best whether you're training hard or keeping up with life. Visit gamedaymenshealth.com/bengreenfield for a free testosterone test and consultation at a clinic near you. BEAM Minerals: If you want to up your mineral game, give BEAM Minerals a try. Go to beamminerals.com and use code BEN at checkout for 20% off your order. Thrive Market: Discover how Thrive Market delivers premium, clean-label groceries from top brands like Simple Mills and Primal Kitchen at up to 30% off retail prices, making healthy eating accessible without compromising your budget or values. Skip the junk without overspending—visit thrivemarket.com/ben for 30% off your first order plus a FREE $60 gift. BiOptimizers MassZymes: MassZymes is a powerful best-in-class enzyme supplement that improves digestion, reduces gas and bloating, and provides relief from constipation. Go to bioptimizers.com/ben and use code ben10 for 10% off your order. BON CHARGE: BON CHARGE is a holistic wellness brand with a wide range of products that naturally address the issues of modern life. Their products can help you sleep better, perform better, recover faster, balance hormones, reduce inflammation, and so much more. Go to boncharge.com/GREENFIELD and use coupon code GREENFIELD to save 15%.See omnystudio.com/listener for privacy information.

Vaughn Halliday, MSc, CFM, SFP, FMP, PMP, ProFM is Manager of Support Services and Facilities for the Central Bank of Trinidad & Tobago where he is a seasoned management executive with a specialized focus on facilities and project management, underpinned by a fervent commitment to sustainability. Mike Petrusky asks Vaughn why he believes that FM professionals need to lead with purpose, adapt with precision, and invest in people as much as they do in technology. They discuss the constant tension between short-term operational demands and long-term asset stewardship which often leads to deferred maintenance and reactive decision-making and Vaughn shares how the effective use of data from CMMS and BMS platforms is essential for driving strategic outcomes. He says that facility managers should move beyond a maintenance mindset and embrace FM as a strategic enabler of business outcomes by investing in training and credential programs at events like IFMA's World Workplace. The future of FM is already here, with AI, IoT, and smart systems reshaping how assets are managed, so Mike and Vaughn encourage and inspire you to be an Asset Champion in your organization! Connect with Vaughn on LinkedIn: https://www.linkedin.com/in/vaughn-halliday/ Learn more about IFMA: https://www.ifma.org/ Explore Eptura™: https://eptura.com/ Discover free resources and explore past interviews at: https://eptura.com/discover-more/podcasts/asset-champion/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

In our first episode of On Brand: Taylor's Version, we're joined by Sinéad O'Sullivan — aerospace engineer turned business strategist, former head of Strategy at Harvard Business School, professor, and co-founder of a global investment fund. She's advised everyone from NASA to prime ministers … and she also happens to be in the top 0.01% of Taylor Swift fans worldwide. Her new book, Good Ideas and Power Moves: Business Lessons from Taylor Swift, hits shelves this week — and she's here to share why Taylor isn't just a pop star, but one of the sharpest strategists of our time. What You'll Learn in This Episode Why “doing strategy” is more than PowerPoints and wish lists How Taylor Swift creates interlinked universes across her albums What it means to be anti-fragile and thrive in chaotic environments How storytelling can be leveraged as a business strategy Why Taylor Swift is her own product and outperforms traditional companies Episode Chapters (00:00) Intro (01:00) Getting Started with Taylor's Version (01:35) Reputation Era Story Prompt and Misunderstandings (03:40) Doing Strategy the Taylor Way (08:10) Building Worlds Not Products (12:30) Lessons for Brands and Community (17:50) Fearless Era Story Prompt and Courage (24:20) Anti-Fragile Moves and Thriving in Chaos (28:10) Timing, Reverse Acquisitions, and Big Picture Strategy (38:30) Where to Connect with Sinéad About Sinéad O'Sullivan Sinéad O'Sullivan is an aerospace engineer turned business strategist, former head of strategy at Harvard Business School, professor, writer, and co-founder of a global investment fund. She has advised organizations from NASA to prime ministers and is the author of Good Ideas and Power Moves: Business Lessons from Taylor Swift. O'Sullivan has a BA in engineering, an MSc in finance, and a PhD in strategy. What Brand Has Made Sinéad Smile Recently? Sinéad shared that she's been smiling at the creative universe built around Barbie. From specialty cars to Airbnbs, the way Barbie has expanded into a full cultural ecosystem reminded her of the worlds Taylor Swift builds with her albums—demonstrating creativity, collaboration, and clever brand storytelling. Resources & Links Connect with Sinéad on LinkedIn. Sinéad's website. Sinéad's Substack. Sinéad's new book, Good Ideas and Power Moves: Ten Lessons for Success from Taylor Swift. Listen & Support the Show Watch or listen on Apple Podcasts, Spotify, YouTube, Amazon/Audible, TuneIn, and iHeart. Rate and review on Apple Podcasts and Spotify to help others find the show. Share this episode — email a friend or colleague this episode. Sign up for my free Story Strategies newsletter for branding and storytelling tips. On Brand is a part of the Marketing Podcast Network. Until next week, I'll see you on the Internet! Learn more about your ad choices. Visit megaphone.fm/adchoices

We love to hear from our listeners. Send us a message.On episode 111 of Cell & Gene: The Podcast, Host Erin Harris talks to Ernexa Therapeutics' President and CEO, Sanjeev Luther, about how the company is advancing cell therapy innovation for cancer and autoimmune disease through engineered induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs). Luther shares how Ernexa's synthetic, standardized, off-the-shelf iMSCs are designed to overcome historic hurdles in MSC therapy, including variability, scalability, and manufacturing complexity, by leveraging master cell banks, precise gene editing, and novel product engineering. He also shares insights into the process of developing pro- and anti-inflammatory iMSCs for oncology and autoimmunity.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Lauren Juliff is Climate and Sustainability Product Lead and Head of UK Institutional at Storebrand Asset Management UK. Her educational background is in science and she has a MSc in Climate Change: Environment, Science and Policy. We start our conversation with Lauren's background and a passion for dance that she has carried throughout her life. We mention this as a reminder to take time to nurture health, and joy, even in the small moments. Moving then to her professional career we discuss the evolution of climate and sustainability products, and how she was motivated to pursue a post graduate degree in the area of climate change policy. We discuss then how this enriched her approach to product development and solution building and look at the outlook for this and similar strategies.  Why we made this? Lauren is a passionate industry member with a unique blend of an academic background in Climate Change, Environment, Science and Policy as well as an understanding as to how sustainability products are fashioned and delivered.  Why we think you may like it? A growing body of investors is interested in climate and sustainability products, and this podcast provides insights on product positioning, the evolving nature of client demand  With thanks to Baillie Gifford for sponsoring Series 4 of 2025. Baillie Gifford is a long-term investment manager, dedicated to discovering the innovations and changemakers that deliver exceptional growth opportunities for its clients.

We discuss the May 16 FDA approval of the first blood test to diagnose Alzheimer disease. This landmark approval marks a significant shift in how Alzheimer disease is identified, moving away from more traditional methods or invasive methods. Our guests, Howard Fillit, the Alzheimer's Drug Discovery Foundation, and Anthony “Nino” Sireci, MD, MSc, Eli Lilly and Company, help us understand this “huge accomplishment" and how it may be able to transform the diagnostic landscape from one of nihilism to one of hope and early intervention.

Want the latest news, analysis, and price indices from power markets around the globe - delivered to your inbox, every week?Sign up for the Weekly Dispatch - Modo Energy's unmissable newsletter.As renewables take a larger share of the power mix, the need for flexibility in electricity markets has never been greater. But while the technology exists. From batteries and demand response to interconnectors the challenge lies in creating the right market structures and incentives to bring it all together.Today's power markets were designed around centralised fossil generation. For flexibility to scale, they must evolve, ensuring that short-term trading, ancillary services, and long-term contracts all work in harmony. Without that, renewable integration will stall, and the cost of balancing the grid will rise.In this episode of Transmission, Quentin is joined by Rasmus Rode Mosbæk to explore the future of energy trading and flexibility markets. They discuss how market design can enable faster renewable integration, why transparency and liquidity matter, and what lessons can be drawn from other European systems. Over the course of the conversation, they discuss:Why flexibility is the missing piece in renewable integration.How market design shapes investment and innovation in storage.The growing role of short-term trading in balancing the grid.Lessons from European power markets on flexibility and liquidity.What's needed to unlock the full potential of demand-side response.About our guestRasmus Rode Mosbæk is the CEO and Founder of Hybrid Greentech, a Danish software company specialising in intelligent energy storage solutions. With an MSc and PhD in energy systems, Rasmus combines deep technical expertise with commercial insight to deliver smarter ways of integrating renewables into the grid. At Hybrid Greentech, he leads the development of HERA, an AI-powered platform that optimises virtual power plants and battery storage, helping asset owners maximise revenues, extend asset lifetimes, and strengthen grid stability. For more information on Hybrid Greentech, head to their website.About Modo EnergyModo Energy helps the owners, operators, builders, and financiers of battery energy storage solutions understand the market - and make the most out of their assets.All of our podcasts are available to watch or listen to on the Modo Energy site. To keep up with all of our latest updates, research, analysis, videos, podcasts, data visualizations, live events, and more, follow us on LinkedIn. Check out The Energy Academy, our bite-sized video series breaking down how power markets work.

Want the latest news, analysis, and price indices from power markets around the globe - delivered to your inbox, every week?Sign up for the Weekly Dispatch - Modo Energy's unmissable newsletter.As renewables take a larger share of the power mix, the need for flexibility in electricity markets has never been greater. But while the technology exists. From batteries and demand response to interconnectors the challenge lies in creating the right market structures and incentives to bring it all together.Today's power markets were designed around centralised fossil generation. For flexibility to scale, they must evolve, ensuring that short-term trading, ancillary services, and long-term contracts all work in harmony. Without that, renewable integration will stall, and the cost of balancing the grid will rise.In this episode of Transmission, Quentin is joined by Rasmus Rode Mosbæk to explore the future of energy trading and flexibility markets. They discuss how market design can enable faster renewable integration, why transparency and liquidity matter, and what lessons can be drawn from other European systems. Over the course of the conversation, they discuss:Why flexibility is the missing piece in renewable integration.How market design shapes investment and innovation in storage.The growing role of short-term trading in balancing the grid.Lessons from European power markets on flexibility and liquidity.What's needed to unlock the full potential of demand-side response.About our guestRasmus Rode Mosbæk is the CEO and Founder of Hybrid Greentech, a Danish software company specialising in intelligent energy storage solutions. With an MSc and PhD in energy systems, Rasmus combines deep technical expertise with commercial insight to deliver smarter ways of integrating renewables into the grid. At Hybrid Greentech, he leads the development of HERA, an AI-powered platform that optimises virtual power plants and battery storage, helping asset owners maximise revenues, extend asset lifetimes, and strengthen grid stability. For more information on Hybrid Greentech, head to their website.About Modo EnergyModo Energy helps the owners, operators, builders, and financiers of battery energy storage solutions understand the market - and make the most out of their assets.All of our podcasts are available to watch or listen to on the Modo Energy site. To keep up with all of our latest updates, research, analysis, videos, podcasts, data visualizations, live events, and more, follow us on LinkedIn. Check out The Energy Academy, our bite-sized video series breaking down how power markets work.

Felix Frenzel is the Founding Partner of Kadan Capital, a Singapore-headquartered early-stage venture capital firm backing category-defining startups across Southeast Asia and beyond. At Kadan, he focuses on high-impact companies in fintech and artificial intelligence, targeting ventures with strong early traction and potential for rapid scale.Before co-founding Kadan Capital, Felix built his expertise across investment management and strategy consulting. He was an Investment Manager at Antler, a leading global early-stage VC platform, and a strategy consultant at Bain & Company, where he advised top-tier clients on transformative growth strategies. Earlier in his career, he gained experience in public equity investing, adding depth to his financial acumen.Felix's passion for investing runs deep. At just sixteen, he launched a small fund focused on European equities—a first step that reflects both his entrepreneurial drive and early fascination with capital markets.He holds an MBA from INSEAD, an MSc in International Finance from HEC Paris, and a BSc in Economics from the University of Bonn.LinkedIn: https://www.linkedin.com/in/felixfrenzel/

durée : 00:04:09 - Le Fil éco - De la mer aux médias, les armateurs MSC, Maersk, CMA CGM et COSCO étendent leur empire. Arnaud Orain s'interroge : vers un capitalisme piloté par les océans ? - réalisation : Nicolas Berger

In this special episode, the creators of SAMR, TPACK, Triple E, SETI, and GenAI-U reflect on how their views of AI in education have evolved since the launch of ChatGPT in November 2022. They share hard lessons learned and insights gleaned, offering a candid look at the ups and downs in their journey through periods of awe, skepticism, and embracing AI's potential. As they prepare to head back to school, they discuss their personal AI use, how their own kids are using AI, and their updated thinking on cheating prevention strategies. The group expands the lens to examine tech companies' AI promises, why Grammarly's new feature is shaking up grading, and how AI is impacting our relationships on many levels. They conclude by sharing how they plan to approach AI differently as they head back to school this term. Follow on X: @CFKurban @hcrompton @lkolb @punyamishra @jonHarper70bd @bamradionetwork Dr. Punya Mishra (punyamishra.com) is the Associate Dean of Scholarship and Innovation at the Mary Lou Fulton Teachers College at Arizona State University. He has an undergraduate degree in Electrical Engineering, two Master's degrees in Visual Communication and Mass Communications, and a Ph.D. in Educational psychology. He co-developed the TPACK framework, described as “the most significant advancement in technology integration in the past 25 years.” Dr. Caroline Fell Kurban is the advisor to the Rector at MEF University. She was the founding Director of the Center of Research and Best Practices for Learning and Teaching (CELT) at MEF University and teaches in the Faculty of Education. She holds a BSc in Geology, an MSc in TESOL, an MA in Technology and Learning Design, and a PhD in Applied Linguistics. Fell Kurban is currently the head of the Global Terminology Project and the creator of the GenAI-U technology integration framework. Dr. Liz Kolb is a clinical professor at the University of Michigan and the author of several books, including Cell Phones in the Classroom and Help Your Child Learn with Cell Phones and Web 2.0. Kolb has been a featured and keynote speaker at conferences throughout the U.S. and Canada. She created the Triple E Framework for effective teaching with digital technologies and blogs at cellphonesinlearning.com. Dr. Puentedura is the Founder and President of Hippasus, a consulting practice focusing on transformative applications of information technologies to education. He has implemented these approaches for over thirty years at various K-20 institutions and health and arts organizations. He is the creator of the SAMR model for selecting, using, and evaluating technology in education and has guided multiple projects worldwide. Dr. Helen Crompton is the Executive Director of the Research Institute for Digital Innovation in Learning at ODUGlobal and Professor of Instructional Technology at Old Dominion University. Dr. Crompton earned her Ph.D. in educational technology and mathematics education from the University of North Carolina at Chapel ill. Dr. Crompton is recognized for her outstanding contributions and is on Stanford's esteemed list of the world's Top 2% of Scientists. She is the creator of the SETI framework. She frequently serves as a consultant for various governments and bilateral and multilateral organizations, such as the United Nations and the World Bank, on driving meaningful change in educational technology.

Jack Waverley is a senior lecturer in marketing at the University of Manchester. He uses marketing and consumer research to protect and promote the interests of all animals, including humans. Jack teaches on a range of BSc and MSc courses in the Fashion, Business, and Technology (FBT) group. He also supervises a number of PhD and dissertation students. He is an academic expert member of the Academy of Marketing and a member of the Vegan Society's Research Advisory Committee.In Sentientist Conversations we talk about the most important questions: “what's real?”, “who matters?” and "how can we make a better world?"Sentientism answers those questions with "evidence, reason & compassion for all sentient beings." The video of our conversation is ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.00:00 Clips00:52 Welcome- Jack's talk at VARC 2025- "The VARC conference is like being in the future...where we want to get to... it really does feel like you've jumped forward 10 years"02:49 Jack's Intro- A marketing consumer researcher... focusing both onconsumption of animals and consumption for animals- "Markets as a system of morals... material objects moving around... infrastructures"- "How we move from one system to another"- The AI question "I very much adopt a sentiocentric or Sentientist perspective"- "The reason I'm concerned about animals is because they are sentient"- "If AI were to become sentient... then of course they would fall within... my moral circle"- "Most people think about 'what can AI do for me... for humans?... How does AI affect humanity?'"- "I'm much more interested in 'what can we do for AI?'... our responsibilities for AI... how can AI help post-humanity, more than humanity, all sentient beings."- "I've ended up in this... very anthropocentric tradition... marketing and consumer research... but bringing in animals and bringing in AI"- A new field of #SentientistMarketing ?05:14 What's Real- Growing up in "a nominally Christian household... but we never went to church... more agnostic"- "There was never an explicit framework of... this is why these things are good or bad"- A liberal, progressive upbringing "live and let live"- "It wasn't quite a blank slate [re: moral thinking] but it was as close as you probably get"- "Broadly naturalistic is my baseline... interested in biology, chemistry, physics, mathematics... scientific ways of approaching the world"- "I didn't really go out looking for any kind of revelation... [or] any strict rules... [or] some sort of authority figure"- "I didn't mind other people having religion but for me it just didn't make sense... I was naturalistic"31:44 What and Who Matters?35:50 A Better World?01:21:40 Follow Jack:- Jack at Manchester University- Jack on LinkedIn (please get in touch)And more... full show notes at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sentientism.info⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Sentientism is “Evidence, reason & compassion for all sentient beings.” More at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sentientism.info⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Join our⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠"I'm a Sentientist" wall⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ via⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ this simple form⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Everyone, Sentientist or not, is welcome in our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠groups⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. The biggest so far is ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here on FaceBook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Come join us there!

Chorea describes involuntary movements that are random, abrupt, and unpredictable, flowing from one body part to another. The most common cause of genetic chorea in adults is Huntington disease, which requires comprehensive, multidisciplinary care as well as support for care partners, who may themselves be diagnosed with the disease. In this episode, Aaron Berkowitz, MD, PhD FAAN speaks with Kathryn P. L. Moore, MD, MSc, author of the article “Huntington Disease and Chorea” in the Continuum® August 2025 Movement Disorders issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology at the University of California San Francisco in the Department of Neurology in San Francisco, California. Dr. Moore is an assistant professor and director of the Parkinson's Disease and Movement Disorders Fellowship in the department of neurology at Duke University in Durham, North Carolina. Additional Resources Read the article: Huntington Disease and Chorea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Guest: @KatiePMooreMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Berkowitz: This is Dr Aaron Berkowitz with Continuum Audio, and today I'm interviewing Dr Kathryn Moore about her article on diagnosis and management of Huntington disease and chorea, which appears in the August 2025 Continuum issue on movement disorders. Welcome to the podcast, Dr Moore. Could you please introduce yourself to our audience? Dr Moore: Yeah, thank you so much. I'm so excited to be here. I'm Dr Moore. I'm an assistant professor of neurology at Duke University, where I work as a movement disorder specialist. I run our fellowship there and help with our residency program as well. So, I'm excited to speak with our listeners about chorea today. Dr Berkowitz: Fantastic. And we're excited to talk to you about chorea. So, as a general neurologist myself, I only see chorea pretty rarely compared to other movement disorders like tremor, myoclonus, maybe the occasional tic disorder. And like anything I don't see very often, I always have to look up the differential diagnosis and how to evaluate a patient with chorea. So, I was so glad to read your article. And next time I see a patient with chorea, I know I'll be referring to your article as a great reference to have a framework for how to approach it. I hope our readers will look at all these helpful tables on differential diagnosis based on distribution of chorea in the body, potential etiologies, time course of onset and evolution, associated drug-induced causes, what tests to send. So, I highly recommend our listeners read the article. Keep those tables handy for when a patient comes in with chorea. I'm excited to pick your brain about some of these topics today. First, how do you go about distinguishing chorea from other hyperkinetic movement disorders when you see a patient that you think might have chorea? Dr Moore: One of the wonderful things about being a movement disorder specialist is we spend a lot of time looking at movements and training our brain to make these distinctions. The things that I would be looking out for chorea is involuntary, uncontrolled movements that appear to be brief and flowing from one part of the body to another. So, if you can watch a patient and predict what movements they're going to do, this probably isn't chorea. And it should be flowing from one part of the body to another. So, not staying just in one part of the body or having sustained movements. It can be difficult to distinguish between a tic or dystonia or myoclonus. Those things tend to be more predictable and repetitive than the chorea, which tends to be really random and can look like dancing. Dr Berkowitz: That's very helpful. So, once you've decided the patient has chorea, what's your framework for thinking about the differential diagnosis of the cause of the patient's chorea? Dr Moore: Well, that could be really challenging. The differential for chorea is very broad, and so the two things that I tend to use are age of the patient and acuity of onset. And so, if you're thinking about acute onset of chorea, you're really looking at a structural lesion like a stroke or a systemic issue like infection, hyperglycemia, etc. Where a gradually progressive chorea tends to be genetic in nature. When you're thinking about the difference between a child and an adult, the most common cause of chorea in a child is Sydenham's chorea. And actually, the most common cause of chorea that I tend to see is Parkinson's disease medication. So, if anybody's seen dyskinesia in Parkinson's disease, you've seen chorea. But it's those two things that I'm using, the age of the patient and the acuity. Somewhere in the middle, though---so, if you have subacute onset of chorea---it's important to remember to think about autoimmune conditions or paraneoplastic conditions because these are treatable. Dr Berkowitz: That's very helpful. So, like in any chief concern in neurology, we're using the context like the age and then the time course. And then a number of other helpful points in your article about the distribution of chorea in the body. Any comments you'd like to make about- we have this very helpful table that I thought was very interesting. So, you really get deep into the nuances of chorea and the movement disorder specialist expert level. Are there any aspects of parts of the body affected by chorea or distribution of chorea across the body that help you hone your differential diagnosis? Dr Moore: Certainly. I think where the chorea is located in the body can be helpful, but not as helpful as other conditions where you're localizing a lesion or that sort of thing. Because you can have a systemic cause of chorea that causes a hemichorea; that you can have hyperglycemia causing a hemichorea, or even Sydenham's chorea being a hemichorea. But things that we think about, if the forehead is involved, I would think about Huntington's disease, although this is not pathognomonic. And if it's involving the face or the mouth, you can think about neuroacanthocytosis or, more commonly, tardive dyskinesia. Hemichorea would make me think about some of those systemic issues like hyperglycemia, Sydenham's chorea, those sorts of things, but I would rely more on the historical context and the acuity of presentation than the distribution itself. Dr Berkowitz: Got it. That's very helpful. So those can be helpful features, but not sort of specific for any particular condition. Dr Moore: Exactly. Dr Berkowitz: Yeah, I often see forehead chorea mentioned as sort of specific to Huntington's disease. Since I don't see much Huntington's disease myself, what does forehead chorea look like? What is the forehead doing? How do you recognize that there is chorea of the forehead? It's just sort of hard for me to imagine what it would look like. Dr Moore: It's really tricky. I think seeing the eyebrows go up and down or the brows furrow in an unpredictable way is really what we're looking for. And that can be hard if you're having a conversation. My forehead is certainly animated as we're talking about one of my favorite topics here. One of the tricks that I use with the fellows is to observe the forehead from the side, and there you can see the undulation of the forehead muscles. And that can be helpful as you're looking for these things. I think where it's most helpful to use the forehead is if you're trying to determine if someone with a psychiatric history has tardive dyskinesia or Huntington's disease, because there can be quite a lot of overlap there. And unfortunately, patients can have both conditions. And so, using the forehead movement can be helpful to maybe direct further testing for Huntington's disease. Dr Berkowitz: Oh, wow, that's a very helpful pearl. So, if you see, sort of, diffuse chorea throughout the body and the forehead is involved, to my understanding it may be less specific. But in the context of wondering, is the neuropsychiatric condition and movement disorder related by an underlying cause in the case of seeing orofacial dyskinesias, is the relationship a drug having caused a tardive dyskinesia or is the whole underlying process Huntington's, the absence of forehead might push you a little more towards tardive dyskinesia, presuming there is an appropriate implicated drug and the presence of forehead chorea would really clue you in more to Huntington's. Did I understand that pearl? Dr Moore: That's exactly right, and I'm glad you brought up the point about making sure, if you're considering tardive dyskinesia, that there has been an appropriate drug exposure. Because without that you can't make that diagnosis. Dr Berkowitz: That's a very helpful and interesting pearl, looking at the forehead from the side. That is a movement disorders pearl for sure. Sort of not just looking at the forehead from one angle and trying to figure out what it's doing, but going to look at the patient in profile and trying to sort it out. I love that. Okay. So, based on the differential diagnosis you would have crafted based on whether this is sort of acute, subacute, chronic, the age of the patient, whether it's unilateral, bilateral, which parts of the body. How do you go about the initial evaluation in terms of laboratory testing, imaging, etc.? Dr Moore: Well, certainly in an acute-onset patient, you're going to get a number of labs---and that's listed out for you in the paper---and consider imaging as well, looking for an infarct. One thing our learners will know is that sort of the typical answer to what's the infarct causing hemichorea would be the subthalamic nucleus. But really, those infarcts can be almost anywhere. There are case reports for infarcts in a wide variety of places in the brain leading to hemichorea. So, I think some general blood work and an MRI of the brain is a good place to start. For someone who has a more chronic course of the development of chorea, there are certain labs that I would get---and an MRI, because if you get an MRI and there's heavy metal deposition or other disease, structurally, that indicates a certain condition, that can help you pretty considerably. But otherwise, I'm looking for inflammatory markers, heavy metals, HIV, some general other things that are outlined, to help make sure that I'm not missing something that's treatable before I go down the route of genetic testing. And we may talk about this in a little bit, but if you start out with genetic testing and then you sort of have to back up and do more systemic testing, that can be very disjointed when it comes to good patient care. Dr Berkowitz: That's very helpful. So yeah, if it's acute, obviously this is the most straightforward scenario, acute and unilateral. We're imagining something lesional, as you said, either a stroke or---not sort of sudden, but fast, but not sudden---you might think of another structural lesion. Toxoplasmosis, right, has an affinity for the basal ganglia if you were seeing this in a patient who is immunocompromised. But in a case that, probably as you alluded to, sort of what we would see most commonly in practice, those still relatively rare, sort of subacute to chronic symmetric chorea. There's a long list of tests that are recommended. In your article and in other texts, I've read lupus testing, anti-phospholipid antibodies… but the list is long. I'll refer readers to your article. Out of curiosity as a specialist, how often do you see any of these labs come back revealing any underlying diagnosis in a patient who's otherwise healthy and just has developed chorea and comes to you with that chief concern? I feel like I've sent that mega-workup a few times; I'm obviously a general neurologist, but not nearly as many times as you have been. It's- I can't remember a time where something has come up, maybe an ANA one to forty or something like this that we don't think is relevant. But in your practice, how often do you end up finding a reversible cause in the laboratory testing versus ending up starting to go down the genetic testing route, which we'll talk about in a moment? Dr Moore: It's not common, but it is important that we capture these things. Because for a lot of those laboratory tests, there are treatments that are available, or other health implications if those come back positive. So, the case I think of is a polycythemia vera patient who had diffused subacute onset chorea and was able to be treated, was temporarily managed with medication for her chorea, and as her PV improved, she was able to come off those medications. As I was alluding to before---and I'm sure we'll talk about genetic testing---if you test for HD and it's negative, do you go down the route of additional expensive genetic testing, or do you then circle back and go, oops, I missed this treatable condition? As we talk about genetic testing as well, getting HD testing is a pretty involved process. And so, we want to make sure we are checking all those boxes before we move forward. So, it's not common, but we do catch some treatable conditions, and that's really important not to miss. Dr Berkowitz: That's very interesting. So, you diagnosed that polycythemia vera by blood smear, is that how you make the diagnosis? Dr Moore: Yes. Dr Berkowitz: And is that a once-in-a-career-so-far type of thing, or does that happen time to time? Dr Moore: For me, that's a once-so-far, but I don't doubt that I'll see it again. Dr Berkowitz: Great. And how about lupus and some of these other things we look for in the absence of other systemic features? Have you picked up any of these or heard of colleagues picking up something on laboratory testing? They said, oh, this patient came in for a referral for genetic testing, negative Huntington's disease. And good news, we found polycythemia vera; good news, we found undiagnosed lupus and we reversed it. I'm just curious, epidemiologically, seeing these long lists and not having the subspecialty practice that you do, how often you find a reversible cause like we do for neuropathy all the time, right? Oh, it's diabetes, it's B12---maybe not reversible, but preventing progression---or reversible dementia work up. You get so excited when you find low B12 and you replete the patient's B12, and they get better when they had been concerned they were developing an irreversible condition. How often does one in your subspecialty find a reversible cause on that initial mega-lab screen? Dr Moore: I think it's really uncommon, and maybe the folks that do are caught by someone else that never make it to Huntington's clinic, but I don't tend to see those cases. There are, of course, case reports and well-described in the literature about lupus and movement disorders and things of that nature, but that doesn't come to our clinic on a regular basis for sure. Dr Berkowitz: Got it. That's helpful to hear. Well, we've alluded to genetic testing a number of times now, so let's go ahead and talk about it. A lot of your article focuses on Huntington disease, and I was thinking about---in the course of our medical training in medical school, and then neurology residency, for those of us who don't become movement disorder experts like yourself---we learn a lot about Huntington disease. That's sort of the disease that causes chorea, until we later learned there are a whole number of diseases, not just the reversible causes we've been talking about, but a number of genetic diseases which you expertly reviewing your article. So, what are some of the red flags that suggest to you that a patient with chronically progressive chorea---and whom you're concerned for Huntington's or another genetic cause---what are some things you notice about the history, about the exam, the symptoms, the signs, the syndrome, that suggest to you that, actually, this one looks like it might not turn out to be HD. I think this patient might have something else. And as you have alluded to, how do you approach this? Do you send HD testing, wait for it to come back, and then go forward? Are there genetic panels for certain genetic causes of chorea? Do you skip just a whole exome sequencing, or will you miss some of the trinucleotide repeat conditions? How do you approach this in practice? Dr Moore: I'll try to tackle all that. One thing I will say is that a lot of patients with chorea, regardless of the cause, can look very similar to one another. So, if you're looking at chronic onset chorea, perhaps with some neuropsychiatric features, I'm going to most often think about HD because that's the most common cause. Certainly, as we mentioned before, if there's a lot of tongue protrusion, I would think about the acanthocytic conditions, neurocanthocytosis and McCloud syndrome. But generally in those conditions, we're looking at HD as the most likely cause. Certainly, if there is epilepsy or some other syndromic types of things going on, I may think more broadly. But it's important to know that while HD, as you mentioned, is the cause of chorea, many of our patients will have parkinsonism, tics, dystonia, a whole host of other movement phenomenologies. So, that wouldn't dissuade me from thinking about HD. When we think about the kind of patients that you're describing, upwards of 95% of those people will have Huntington's disease. And the process for genetic testing is fairly involved. The Huntington's Disease Society of America has organized a set of recommendations for providers to go about the process of genetic testing in a safe and supportive way for patients and their families. And so that's referred to in the article because it really is important and was devised by patients and families that are affected by this disease. And so, when we're thinking about genetic testing for HD, if I reveal that you have HD, this potentially affects your children and your parents and your siblings. You can have a lot of implications for the lives and health and finances of your family members. We also know that there is high suicidality in patients with HD, in patients who are at risk for HD; and there's even a higher risk of suicidality in patients who are at risk but test negative for HD. So, we do recommend a supportive environment for these patients and their families. And so, for presymptomatic patients or patients who are at risk and don't have chorea, this involves making sure we have, sort of, our ducks in a row, as it were, when we think about life insurance, and, do you have somebody supportive to be with you through this journey of genetic testing, no matter what the results are? So, oftentimes I'll say to folks, you know, there's this 20-page policy that I encourage you to look at, but there are Huntington's Disease Centers of Excellence across the country that are happy to help you with that process, to make sure that the patients are well supported. This is an individual genetic test because, as you mentioned, it is a CAG repeat disorder. And unfortunately, there is no chorea panel. So, if an HD test comes back negative, what we'll do then is think about what's called the HD phenocopies. As I mentioned before, some of these patients who look like they have HD will have a negative HD test. And so, what do you do then? Well, there's a handful of phenocopies---so, other genetic mutations that cause a very similar presentation. And so, we try to be smart, since there's not a panel, we try to be smart about how we choose which test to do next. So, for instance, there's a condition called DRPLA that is present in an African-American family here in my area, in North Carolina, as well as in Japan. And so, if someone comes from those backgrounds, we may decide that that's the next test that we're going to do. If they are white European descent, we may consider a different genetic test; or if they're sub-Saharan African, we may choose a different one from that. However, even if you do a really thorough job, all those blood tests, all those genetic tests, you will occasionally get patients that you can't find a diagnosis for. And so, it's important to know even when you do a good job, you may still not find the answer. And so, I think trying to do things with this complex of the presentation in a systematic way for yourself so you're not missing something. So, going back to our answer about, how do I look at lupus and polycythemia vera and all of that, to think about it in a systematic way. That when you get to the end and you say, well, I don't have an answer, you know you've tried. Dr Berkowitz: That's very helpful to hear your approach to these challenging scenarios, and also how to approach the potential challenging diagnosis for patients and their families getting this diagnosis, particularly in the presymptomatic phase. And your article touches on this with a lot of nuance and thoughtfulness. So, I encourage our listeners to have a read of that section as well. So, last here, just briefly in our final moments, you discuss in your article the various symptomatic treatments for chorea. We won't have time to go into all the details of all the many treatments you discussed, but just briefly, how do you decide which medication to start in an individual patient with chorea for symptomatic management? What are some of the considerations related to the underlying condition, potential side effect profiles of the particular medications, or any other considerations just broadly, generally, as you think about choosing one of the many medications that can be used to treat chorea? Dr Moore: Certainly. So, there is a group of FDA-approved medications, VMAT2 inhibitors, that we can choose from, or the off-label use of neuroleptics. And so, there's a lot of things that go into that. Some of that is insurance and cost and that sort of thing, and that can play a role. Others are side effects. So, for the VMAT2 inhibitors, they all do have a black box warning from the FDA about suicidality. And so, if a patient does struggle with mental health, has a history of suicidality, psychiatric admissions for that sort of thing, then I would be more cautious about using that medication. All patients are counseled about that, as are their families, to help us give them good support. So, the neuroleptics do not tend to have that side effect and can help with mood as well as the chorea and can be helpful in that way. And some of them, of course, will have beneficial side effects. So, olanzapine may help with appetite, which can be important in this disease. So, the big considerations would be the black box warning and suicidality, as well as, are we trying to just treat chorea or are we treating chorea and neuropsychiatric issues? Dr Berkowitz: Fantastic. Thank you for that overview. And again, for our listeners, there's a lot more detail about all of these medications, how they work, how they're used in different patient populations, their side effects, etc, to be reviewed in your excellent article. Again, today, I've been interviewing Dr Kathryn Moore about her article on diagnosis and management of Huntington's disease in chorea, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining today. And thank you again, Dr Moore. Dr Moore: Thanks for having me. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This is a free preview of a paid episode. To hear more, visit abbieattwoodwellness.substack.comThis might be my favorite conversation we've had on this podcast. It's a conversation I had with Edie Stark (an ED therapist) and Sharon Maxwell (a fat activist and weight-inclusive consultant), and we're answering a very important – very hard – listener question.The essence of it is: “I believe in body liberation and anti-diet culture. But what if I'm just uncomfortable being fat?”Tune in for:* How and why Sharon relates to this listener, and moments where she's worked through this thought* How Ozempic culture impacts the desire for weight loss* What it means to practice self-compassion while living within systemic anti-fatness* Whether changing your body can change discomfort* Times when eating disorder thoughts creep in the most* Discomfort as a signal of something deeper* The role of mental and emotional pain on physical symptoms* Navigating the medical system when it blames body size for everything * SO much more!Support the show: Enjoying this podcast? Please support the show on Substack for bonus episodes, community engagement, and access to "Ask Abbie" at abbieattwoodwellness.substack.com/subscribe Apply for Abbie's Group Membership:Already been at this anti-diet culture thing for a while, but want community and continued learning? Apply for Abbie's monthly membership: https://www.abbieattwoodwellness.com/circle-monthly-groupAbout Edie: Edie Stark, MSc, LCSW is a licensed clinical social worker and the owner of Stark Therapy Group, a psychotherapy group practice specializing in eating disorders, trauma, and anxiety from a humanistic, fat-positive, and inclusive lens. She believes in the value of lived experience being met with clinical knowledge to create a collaborative therapeutic experience for all of the clients. Edie is passionate about Trader Joe's snacks– we talk a little bit about that–dismantling the US healthcare system, and the complete and total takedown of diet culture in no particular order.Learn more at https://starktherapygroup.com/About Sharon:Sharon Maxwell (She/Her) is a mental health advocate and fat activist. She works as a weight inclusive consultant, providing education to treatment centers and healthcare providers on the immense harms of weight stigma. Due to her lived experience facing weight stigma, Sharon provides unique insight and offers practical tools to make treatment centers and healthcare settings safe and accessible for fat folks. Sharon is passionate about breaking down the stigma around eating disorders and working to eradicate societal anti-fat bias. When she's not studying or engaged in her activism work, Sharon can be found exploring San Diego with her dog and her best friend.Read "You Don't Look Anorexic" in New York Times MagazineConnect with Sharon on IG: @heysharonmaxwellLearn more about Sharon: https://www.heysharonmaxwell.com/Social media:Find the show on Instagram: @fullplate.podcastFind Abbie on Instagram: @abbieattwoodwellness Podcast Cover Photography by Anya McInroyPodcast Editing by Brian WaltersThis podcast is ad-free and support comes from your support on Substack. Subscribe HERE.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

In this special edition episode, recorded live at the ASCO Annual Meeting, hosts Shikha Jain, MD, and Edward Kim, MD, honor Healio's 2025 Disruptive Innovators for their positive disruption in the field of hematology/oncology, and for pushing the status quo to improve clinical practice.  •    Welcome to the fourth annual Healio Disruptive Innovator Awards in hematology/oncology. 1:00 •    VK Gadi, MD PhD, presents the Health Equity Award. 3:56 •    The Health Equity Award winner, Ana Velázquez Mañana, MD, makes a speech. 6:00 •    Morgan Collier presents the Woman Disruptor of the Year Award. 7:38 •    Betty S. Pace, MD, accepts the Woman Disruptor of the Year Award. 9:19 •    The Social Media Influencer Award, presented by Eleonora Teplinsky, MD. 11:53 •    Amani Jambhekar, MD, also known as @ajvictorymd on Instagram and TikTok, accepts the Social Media Influencer Award. 13:13 •    Brenda M. Nevidjon, MSN, RN, FAAN, presents the Advanced Practice Trailblazer Award. 14:40 •    Ashley Leak Bryant, PhD, RN, OCN, FAAN, delivers her acceptance speech for the Advanced Practice Trailblazer Award. 16:19 •    Kamal Jethwani, MD, MPH, presents the Patient Voice Award. 18:44 •    Founder Kimberly Richardson, MA, accepts the Patient Voice Award for the Black Cancer Collaborative. 20:44 •    Healio's chief content officer, Joan-Marie Stiglich, ELS, presents the NextGen Disruptor Award to Nazli Dizman, MD. 22:22 •    The Clinical Innovation Award goes to UNC Lineberger Comprehensive Cancer Center for their at-home symptom reporting, led by Ethan Basch, MD, MSc. 24:18 •    Hope S. Rugo, MD, wins the Lifetime Disruptor Award. 26:48 •    The Industry Breakthrough Award goes to Breyanzi (lisocabtagene maraleucel, or liso-cel) from Bristol Myers Squibb. 30:57 •    On behalf of Bristol Myers Squibb, Amy Corrao, MSN, NP-C, accepts the Industry Breakthrough Award. 32:33 •    Thanks to all of the winners, nominees and sponsors! 35:39 •    Thanks for listening. 36:21 We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Read the full coverage from Healio's Disruptive Innovators here.

In today's VETgirl online veterinary continuing education podcast, we interview Dr. Nick Jeffery, BVSc, PhD, MSc, DECVS, DECVN, Professor in Neurology and Neurosurgery from Texas A&M on a recent study by Freeman et al entitled “Percutaneous enzymatic chemonucleolysis of intervertebral disks appears safe and effective in treatment of acute-onset paraparesis and paraplegia in small dogs,” published in JAVMA in March 2025. Can the use of intradiscal chondroitinase ABC (often called "CHASE") injections under fluoroscopic-guidance work as a safe, minimally invasive option for small dogs with acute nonambulatory paraparesis or paraplegia, especially when deep pain perception is intact? If you're a general practitioner who sees a lot of down dogs—and especially if you practice in a Dachshund-heavy region—you'll definitely want to tune in.